Trial Outcomes & Findings for Desipramine in Infantile Neuroaxonal Dystrophy (INAD). (NCT NCT03726996)

NCT ID: NCT03726996

Last Updated: 2020-10-14

Results Overview

The Gross Motor Function Measure (GMFM-66) is a 66 item standardized observational instrument designed and validated to measure change in gross motor function over time in children with cerebral palsy. Items are ordered in terms of difficulty and a unit of change has the same meaning throughout the scale ranging from 0 to 100. 0 = does not initiate, 1 = initiates, 2 = partially completes, 3 = completes. Scoring the GMFM-66 requires the use of a computer program called the Gross Motor Ability Estimator (GMAE). Individual item scores are entered and a mathematical algorithm calculates an interval level total score. The total score is an estimate of the child's gross motor function.

Recruitment status

TERMINATED

Study phase

PHASE4

Target enrollment

4 participants

Primary outcome timeframe

Baseline, 3, 6, 9, and 12 months

Results posted on

2020-10-14

Participant Flow

Participant milestones

Participant milestones
Measure
Children With INAD
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality. Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
Overall Study
STARTED
4
Overall Study
COMPLETED
0
Overall Study
NOT COMPLETED
4

Reasons for withdrawal

Reasons for withdrawal
Measure
Children With INAD
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality. Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
Overall Study
Parent's decision
2
Overall Study
Study early termination
2

Baseline Characteristics

Data collected on one participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Children With INAD
n=4 Participants
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality. Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
Age, Categorical
<=18 years
4 Participants
n=4 Participants
Age, Categorical
Between 18 and 65 years
0 Participants
n=4 Participants
Age, Categorical
>=65 years
0 Participants
n=4 Participants
Sex: Female, Male
Female
3 Participants
n=4 Participants
Sex: Female, Male
Male
1 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Hispanic or Latino
0 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
4 Participants
n=4 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants
n=4 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=4 Participants
Race (NIH/OMB)
Asian
2 Participants
n=4 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=4 Participants
Race (NIH/OMB)
Black or African American
0 Participants
n=4 Participants
Race (NIH/OMB)
White
1 Participants
n=4 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=4 Participants
Race (NIH/OMB)
Unknown or Not Reported
1 Participants
n=4 Participants
Region of Enrollment
United States
4 Participants
n=4 Participants
Gross Motor Function Measure (GMFM-66)
1 units on a scale
n=1 Participants • Data collected on one participant.
Quick Motor Function Test (QMFT)
0 units on a scale
n=1 Participants • Data collected on one participant.

PRIMARY outcome

Timeframe: Baseline, 3, 6, 9, and 12 months

Population: No data collected beyond baseline.

The Gross Motor Function Measure (GMFM-66) is a 66 item standardized observational instrument designed and validated to measure change in gross motor function over time in children with cerebral palsy. Items are ordered in terms of difficulty and a unit of change has the same meaning throughout the scale ranging from 0 to 100. 0 = does not initiate, 1 = initiates, 2 = partially completes, 3 = completes. Scoring the GMFM-66 requires the use of a computer program called the Gross Motor Ability Estimator (GMAE). Individual item scores are entered and a mathematical algorithm calculates an interval level total score. The total score is an estimate of the child's gross motor function.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline, 3, 6, 9, and 12 months

Population: No data collected beyond baseline.

The Quick Motor Function Test (QMFT) is a 16 item, psychometrically robust outcome assessment, validated in children and adults with Pompe disease (a lysosomal storage disorder characterized by progressive muscle weakness). This motor function test observes performance and scores the items separately on a 5-point ordinal scale (ranging from 0 to 4). If items can be performed on both left and right extremities, the right side is taken. A total score is obtained by adding the scores of all items. The total score ranges between 0 and 64 points. A higher score correlates with greater motor function.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline, 3, 6, 9, and 12 months

Population: Data not collected.

The Vineland-3 is a standardized measure of adaptive behavior--the things that people do to function in their everyday lives. It is a norm-based instrument that compares the examinee's adaptive functioning in four domains: Communication, Daily Living Skills, Socialization and Motor Skills to that of others of the same age. A composite score of adaptive behavior is calculated that summarizes the individual's performance across all four domains.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Baseline, 3, 6, 9, and 12 months

Population: No data collected beyond 6 months.

Evidence of ECG changes, specifically, prolonged Q-T interval in response to study drug. The Q-T interval is the time from the start of the Q wave to the end of the T wave. It represents the time taken for ventricular depolarisation and repolarisation, effectively the period of ventricular systole from ventricular isovolumetric contraction to isovolumetric relaxation. Participants with a prolonged Q-T interval at any timepoint is reported.

Outcome measures

Outcome measures
Measure
Children With INAD
n=4 Participants
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality. Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
Number of Participants With Change in Q-T Interval on ECG
1 Participants

PRIMARY outcome

Timeframe: Baseline, 3, 6, 9, and 12 months

Population: No data collected beyond 6 months.

Transaminase values as measured by serum alanine transaminase (ALT) and aspartate transaminase (AST). Participants with abnormal transaminase values at any timepoint is reported.

Outcome measures

Outcome measures
Measure
Children With INAD
n=4 Participants
Infantile neuroaxonal dystrophy (INAD) is an extremely rare autosomal recessive neurodegenerative disorder that has grave clinical outcome and significant morbidity and mortality. Desipramine: Study drug (desipramine) provided in tablet form to be taken daily.
Number of Participants With Abnormal Transaminase Values
0 Participants

Adverse Events

Children With INAD

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Yong-Hui Jiang, MD, PhD

Yale University

Phone: 203-785-2660

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place